	US 12,076,329 B2
	Compositions and methods for enhancing visual function
Ehud Y. Isacoff, Berkeley, CA (US); Johannes Broichhagen, Munich (DE); and Joshua T. Levitz, Ithaca, NY (US)
Assigned to Cornell Univerisity, Ithaca, NY (US); MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., Munich (DE); and The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US); Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Munich (DE); and Cornell University, Ithaca, NY (US)
Filed on May 27, 2021, as Appl. No. 17/332,865.
Claims priority of provisional application 63/032,241, filed on May 29, 2020.
Prior Publication US 2021/0369744 A1, Dec. 2, 2021
Int. Cl. A61K 31/655 (2006.01); A61F 9/00 (2006.01); A61K 9/00 (2006.01); A61K 31/52 (2006.01); A61K 35/76 (2015.01); A61K 38/16 (2006.01); A61K 47/40 (2006.01); A61K 47/60 (2017.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); A61P 27/02 (2006.01)

CPC A61K 31/655 (2013.01) [A61F 9/0008 (2013.01); A61K 9/0048 (2013.01); A61K 31/52 (2013.01); A61K 35/76 (2013.01); A61K 38/16 (2013.01); A61K 47/40 (2013.01); A61K 47/60 (2017.08); A61K 47/65 (2017.08); A61K 47/6849 (2017.08); A61P 27/02 (2018.01)]

30 Claims

1. A composition for intraocular administration, the composition comprising:

A) a conjugate comprising:

a) an affinity agent that specifically binds:

i) a target ligand-binding polypeptide; or

ii) a polypeptide that binds to a target ligand-binding polypeptide;

b) a branched linker; and

c) two or more photoisomerizable regulators, each independently comprising:

i) an azobenzene 460 photoisomerizable group; and

ii) a ligand that binds to the target ligand-binding polypeptide; and

B) a pharmaceutically acceptable excipient suitable for intraocular administration.